Literature DB >> 32949546

Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues.

Ralph H B Benedict1, Maria Pia Amato2, John DeLuca3, Jeroen J G Geurts4.   

Abstract

Multiple sclerosis is a chronic, demyelinating disease of the CNS. Cognitive impairment is a sometimes neglected, yet common, sign and symptom with a profound effect on instrumental activities of daily living. The prevalence of cognitive impairment in multiple sclerosis varies across the lifespan and might be difficult to distinguish from other causes in older age. MRI studies show that widespread changes to brain networks contribute to cognitive dysfunction, and grey matter atrophy is an early sign of potential future cognitive decline. Neuropsychological research suggests that cognitive processing speed and episodic memory are the most frequently affected cognitive domains. Narrowing evaluation to these core areas permits brief, routine assessment in the clinical setting. Owing to its brevity, reliability, and sensitivity, the Symbol Digit Modalities Test, or its computer-based analogues, can be used to monitor episodes of acute disease activity. The Symbol Digit Modalities Test can also be used in clinical trials, and data increasingly show that cognitive processing speed and memory are amenable to cognitive training interventions.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32949546     DOI: 10.1016/S1474-4422(20)30277-5

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  54 in total

1.  Resting state effective connectivity abnormalities of the Papez circuit and cognitive performance in multiple sclerosis.

Authors:  Olga Marchesi; Raffaello Bonacchi; Paola Valsasina; Maria A Rocca; Massimo Filippi
Journal:  Mol Psychiatry       Date:  2022-05-26       Impact factor: 15.992

2.  Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis.

Authors:  Eleonora Virgilio; Domizia Vecchio; Ilaria Crespi; Chiara Puricelli; Paolo Barbero; Giulia Galli; Roberto Cantello; Umberto Dianzani; Cristoforo Comi
Journal:  J Neurol       Date:  2022-01-28       Impact factor: 4.849

Review 3.  Rituximab for people with multiple sclerosis.

Authors:  Graziella Filippini; Jera Kruja; Cinzia Del Giovane
Journal:  Cochrane Database Syst Rev       Date:  2021-11-08

4.  Effect of BDNF Val66Met polymorphism on hippocampal subfields in multiple sclerosis patients.

Authors:  Ermelinda De Meo; Emilio Portaccio; Elio Prestipino; Benedetta Nacmias; Silvia Bagnoli; Lorenzo Razzolini; Luisa Pastò; Claudia Niccolai; Benedetta Goretti; Angelo Bellinvia; Mattia Fonderico; Antonio Giorgio; Maria Laura Stromillo; Massimo Filippi; Sandro Sorbi; Nicola De Stefano; Maria Pia Amato
Journal:  Mol Psychiatry       Date:  2021-10-14       Impact factor: 15.992

5.  Characterizing Relationships Between Cognitive, Mental, and Physical Health and Physical Activity Levels in Persons With Multiple Sclerosis.

Authors:  Emily E Tyszka; Nina Bozinov; Farren B S Briggs
Journal:  Int J MS Care       Date:  2022-09-08

Review 6.  Mind the gap: from neurons to networks to outcomes in multiple sclerosis.

Authors:  Declan T Chard; Adnan A S Alahmadi; Bertrand Audoin; Thalis Charalambous; Christian Enzinger; Hanneke E Hulst; Maria A Rocca; Àlex Rovira; Jaume Sastre-Garriga; Menno M Schoonheim; Betty Tijms; Carmen Tur; Claudia A M Gandini Wheeler-Kingshott; Alle Meije Wink; Olga Ciccarelli; Frederik Barkhof
Journal:  Nat Rev Neurol       Date:  2021-01-12       Impact factor: 42.937

7.  Neuronal hibernation following hippocampal demyelination.

Authors:  Selva Baltan; Safdar S Jawaid; Anthony M Chomyk; Grahame J Kidd; Jacqueline Chen; Harsha D Battapady; Ricky Chan; Ranjan Dutta; Bruce D Trapp
Journal:  Acta Neuropathol Commun       Date:  2021-03-01       Impact factor: 7.801

8.  Validation of the Finnish version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) and evaluation of the applicability of the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) and the Fatigue Scale for Motor and Cognitive Functions (FSMC).

Authors:  Päivi Hämäläinen; Vera Leo; Sebastian Therman; Juhani Ruutiainen
Journal:  Brain Behav       Date:  2021-05-07       Impact factor: 2.708

Review 9.  Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapy-Kynurenines Are Important Players.

Authors:  Dániel Sandi; Zsanett Fricska-Nagy; Krisztina Bencsik; László Vécsei
Journal:  Molecules       Date:  2021-06-05       Impact factor: 4.411

Review 10.  Cognitive Issues in Pediatric Multiple Sclerosis.

Authors:  Emilio Portaccio; Ermelinda De Meo; Angelo Bellinvia; Maria Pia Amato
Journal:  Brain Sci       Date:  2021-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.